CCL2, CCL3, CCL5, CCL7, CXCL8, CXCL9, CXCL10/CCR5, CXCR3(Approved for MS. IFN-β therapy suppresses MS disease activity. Decreases circulating neutrophils in RRMS patients, and showed a decrease in neutrophil infiltration in animal models. Reduced relapse rate reduced (7% for 1.6 MIU, 33% for 8 MIU). Increases relapse-free patients (23% for 1.6 MIU, 50% for 8 MIU). Decreases of CCR5 and CXCR3 expression on T cells. Induces transient CXCL10 increase. High-dose IFN-β suppress CCL17 in peripheral blood.) This evidence concerns the gene CXCL8 and myeloid sarcoma.